The safety of lumiracoxib when used in the treatment of arthritis

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 347-350

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

Cardiovascular outcomes; Gastrointestinal complications; Ibuprofen; Lumiracoxib; Naproxen; Osteoarthritis; TARGET clinical trial

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFECT; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HEART DEATH; HEART PROTECTION; HEMATOCHEZIA; HUMAN; LIVER DYSFUNCTION; MELENA; OSTEOARTHRITIS; RISK REDUCTION; SILENT MYOCARDIAL INFARCTION; STATISTICAL DISTRIBUTION; STOMACH OBSTRUCTION;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; ORGANIC CHEMICALS; STOMACH ULCER;

EID: 14544276356     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.347     Document Type: Article

References (15)

1. SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364 665-674.
2. FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364:675-684.
3. LAINE L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology (2001) 120 594-606.
4. ANTITHROMBOTIC TRIALIST' COLLABORATIVE: Collaborative meta-analysis of randomised trial of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-86.
5. TANNENBAUM H, BERENBAUM F, REGINSTER JY et al.: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann. Rheum. Dis. (2004) 63:1419-1426.
6. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study - a randomized controlled trial. JAMA (2000) 284 1247-1255.
7. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343 1520-1528.
8. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. (2000) 345:1809-1817.
9. MARSHALL PJ, BERRY JC, WASVARY J et al.: The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann. Rheum. Dis. (2002) 61(Suppl. 1):259 (Abstract SATOO 13).
10. SCOTT G, RORDOFF C, BLOOD P et al.: Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann. Rheum. Dis. (2002) 61(Suppl. 1):259 (Abstract FRI0300).
11. GRIFKA JK, ZACHER J, BROWN JP et al.: Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin. Exp. Rheumatol. (2004) 22 589-596.
12. HAWKEY CC, SVOBODA P, FIEDOROWICZ-FABRYCY IF et al.: Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J. Rheumatol. (2004) 31:1804-1810.
13. KIVITZ AJ, NAYIAGER S, SCHIMANSKY T et al.: Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment. Pharmacol. Ther. (2004) 19:1189-1198.
14. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associates with selective COX-2 inhibitors. JAMA(2001) 286:954-959.
15. FITZGERALD GA: Coxibs and cardiovascular disease. N. Engl. J. Med. (2004) 351:1709-1711.